This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Trethera Corporation. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Kenneth A Schultz: Innovator in Deoxycytidine Kinase Inhibition
Introduction
Kenneth A Schultz is a notable inventor based in Sherman Oaks, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of deoxycytidine kinase inhibitors. His work has the potential to impact the treatment of various medical conditions.
Latest Patents
Kenneth A Schultz holds 1 patent for his invention titled "Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof." This patent describes crystalline forms of compounds that act as deoxycytidine kinase (dCK) inhibitors. The patent outlines methods for creating these crystalline forms, as well as pharmaceutical compositions and medicaments that incorporate them. Furthermore, it details methods for using these crystalline forms in treating conditions, diseases, or disorders that could benefit from modulation of dCK activity.
Career Highlights
Kenneth A Schultz is currently associated with Trethera Corporation, where he continues to advance his research and development efforts. His work at the company focuses on innovative solutions in the pharmaceutical industry, particularly in the realm of cancer treatment and other serious health conditions.
Collaborations
Kenneth collaborates with David C Litzinger, who is also involved in the research and development efforts at Trethera Corporation. Their combined expertise contributes to the advancement of therapeutic options in the field.
Conclusion
Kenneth A Schultz is a prominent inventor whose work in deoxycytidine kinase inhibition holds promise for future medical advancements. His contributions to pharmaceutical sciences are noteworthy and reflect his commitment to improving health outcomes.